Deutsche Bank AG Boosts Stock Position in Abbott Laboratories $ABT

Deutsche Bank AG raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 8.8% in the 4th quarter, Holdings Channel reports. The fund owned 11,579,433 shares of the healthcare product maker’s stock after acquiring an additional 934,778 shares during the quarter. Deutsche Bank AG’s holdings in Abbott Laboratories were worth $1,450,787,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ABT. Freemont Management S.A. raised its stake in shares of Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after buying an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab purchased a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $116,580,000. Thrivent Financial for Lutherans raised its stake in shares of Abbott Laboratories by 24.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after buying an additional 48,286 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new position in shares of Abbott Laboratories during the 3rd quarter worth approximately $185,640,000. Finally, Net Worth Advisory Group purchased a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $1,366,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Performance

ABT opened at $91.27 on Wednesday. The stock has a market cap of $158.97 billion, a P/E ratio of 25.57, a P/E/G ratio of 1.51 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The stock’s 50 day simple moving average is $92.26 and its 200 day simple moving average is $108.64. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. TD Cowen cut their target price on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Oppenheimer cut their target price on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. JPMorgan Chase & Co. cut their target price on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Evercore cut their target price on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Finally, Jefferies Financial Group cut their target price on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $119.09.

Insider Buying and Selling

In other news, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction that occurred on Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction on Monday, April 27th. The shares were bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott secured CE Mark approval for Libre Duo and Libre Duo 10 Day, described as the world’s first dual glucose-ketone sensing technology for people with diabetes. The approval expands Abbott’s diabetes care portfolio and could support future growth in its continuous glucose monitoring business. Article Title
• Positive Sentiment: Goldman Sachs maintained its Buy rating on Abbott Laboratories, which can help reinforce investor confidence after the stock’s recent weakness. Analyst support often matters when sentiment is already focused on valuation and recovery potential. Article Title
• Positive Sentiment: Abbott’s Healthy Food Rx “Food is Medicine” program showed stronger health outcomes when paired with community health worker coaching, including improvements in diabetes management, food insecurity, and physical and mental health. While not a direct earnings driver, it highlights Abbott’s broader healthcare brand and its ability to build programs around chronic disease management. Article Title
• Neutral Sentiment: Abbott was also mentioned in a Motley Fool stock-picking article that called it a “rock-solid” blue-chip name for long-term portfolios. This is broadly supportive of Abbott’s investment image, but it is not company-specific news. Article Title
• Neutral Sentiment: A separate valuation-focused article suggested investors are revisiting whether Abbott is a bargain after its share-price slump. That reinforces the current debate around ABT’s depressed valuation, but it does not add a new catalyst by itself. Article Title
• Negative Sentiment: Abbott remains well below its recent highs and has been under pressure over the past year, so the stock is still trading against a backdrop of weaker longer-term momentum. That context may limit upside until investors see clearer earnings acceleration. Article Title

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.